Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1081-1086

  Finke, J ^a   Brugger, W ^a   Bertz, H ^a   Behringer, D ^a   Kunzmann, R ^a   Weber Nordt, R M ^a   Kanz, L ^a,b   Mertelsmann, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Allogeneic transplantation; CD34; GVHD; Leukemia; Lymphoma; Peripheral blood progenitor cells

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; ETOPOSIDE; FLUCONAZOLE; HEPARIN; ITRACONAZOLE; PAROMOMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGRAFT; ARTICLE; BONE MARROW; CAUSE OF DEATH; CELL SELECTION; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; HUMAN CELL; INFECTION; INFECTIOUS COMPLICATION; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; MOLECULAR BIOLOGY; NEUTROPHIL; NORMAL HUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; THROMBOCYTE COUNT; VEIN OCCLUSION;

ADULT; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIGENS, CD34; BONE MARROW; BONE MARROW CELLS; CHROMATOGRAPHY, AFFINITY; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSORBENT TECHNIQUES; LEUKAPHERESIS; MALE; MIDDLE AGED; SALVAGE THERAPY; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0030476554     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Eaves CJ. Peripheral blood stem cells reach new heights. Blood 1993; 82: 1957-1959.
2. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
3. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
4. Haas R, Witt B, Möhle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
5. Kessinger A. Circulating stem cells - waxing hematopoietic. New Engl J Med 1995; 333: 315-316.
6. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
7. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
8. Bensinger WI, Weaver CH, Appelbaum FR et al Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
9. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
10. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
11. + Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
12. Majolino I, Saglio G, Scimè R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-560.
13. + marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. Blood 1992; 80: 1693-1701.
14. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
15. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-286.
16. Kasai K, Nakamura Y, White R. Amplification of a variable number of tandem repeats (VNTR) locus (pMCT118) by the polymerase chain reaction (PCR) and its application to forensic medicine. J Forensic Sci 1990; 35: 1196-1200.
17. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2795-2801.
18. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
19. Chabannon C, Le Coroller AG, Faucher C et al. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 1995; 4: 171-179.
20. Russell NH, Hunter AE. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant 1994; 13: 353-355.
21. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
22. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187-2193.
23. Kernan NA. T-cell depletion for prevention of graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publishers: Boston, 1994, pp 124-135.
24. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-1407.
25. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
26. Verdonck LF, Dekker AW, De Gast GC et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in tha marrow graft. Blood 1994; 83: 3090-3096.
27. + peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy. Bone Marrow Transplant 1995; 17 (Suppl. 2): (Abstr. 24).
28. Kaufman C, Colson YL, Wren SM et al. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84: 2436-2446.
29. Palathumpat V, Dejbakksh-Jones S, Holm B, Strober S. Studies of CD4- CD8- alpha-beta bone marrow T-cells with suppressor activity. J Immunol 1992; 148: 373-379.
30. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.